Clinical and genetic assessment of the real cardiovascular risk It reclassifies to a higher risk category 7% of the low-risk patients, 15% of the moderate-risk patients and 23% of the high-risk patients. This signifies that for 1 of every 4 patients with high cardiovascular risk and for 1 in every 6 of those with moderate risk, according to the usual risk functions, in reality it is necessary to apply stricter therapeutic objectives.
NeoBona The new generation of Non-Invasive Prenatal Testing (NIPT) it analyzes the cell free fetal DNA in the mother’s blood
A200 Analysis of food intolerance, It is a test which allows the measure of levels on Specific Immunoglobuline G against
Oncology Liquid biopsy tumor DNA sequencing, it utilizes NGS to monitor known tumor mutations in 50 established cancer- associated genes